Physician profile
Shane R Son
NPI 1225180698
$7,600.78
in general payments reported to CMS, 2019-2025
43 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $516 · 2021: $1,352 · 2022: $1,438 · 2023: $1,165 · 2024: $1,193 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,903.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $877.54 | 2021-2025 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $719.27 | 2019-2025 | Spravato |
| Pfizer INC. | $707.16 | 2019-2025 | |
| Lilly USA, LLC | $596.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $526.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.46 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $362.68 | 2022-2025 | |
| Amgen INC. | $306.44 | 2019-2024 | Evenity, Prolia |
| Novo Nordisk INC | $296.84 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $254.91 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Kowa Pharmaceuticals America, INC. | $233.11 | 2021-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $231.67 | 2020-2024 | |
| Mylan Specialty L.P. | $212.89 | 2020-2024 | Yupelri, Yupelri |
| Electromed, INC. | $174.23 | 2022-2024 | Smartvest |
| Astellas Pharma US INC | $160.64 | 2019-2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $119.08 | 2025 | Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $116.67 | 2022 | |
| Exact Sciences Corporation | $115.12 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $78.77 | 2019-2025 | Shingrix, Arexvy |
| Allergan, INC. | $78.71 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $74.34 | 2022-2024 | Eliquis |
| Xeris Pharmaceuticals, INC. | $74.21 | 2024-2025 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $71.77 | 2021 | |
| Bausch Health US, LLC | $68.39 | 2023-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $67.59 | 2019-2020 | |
| Dexcom, INC. | $63.40 | 2020-2022 | |
| Nevro Corp. | $50.54 | 2021-2024 | Senza |
| Azurity Pharmaceuticals, INC. | $49.18 | 2024 | Horizant |
| Viatris Specialty LLC | $43.79 | 2025 | Yupelri |
| Abiomed | $39.09 | 2025 | |
| Arbor Pharmaceuticals, INC. | $35.73 | 2020 | |
| Inspire Medical Systems, INC. | $35.47 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $35.34 | 2020-2021 | |
| Hologic Sales and Service, LLC | $34.41 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Verona Pharma, INC. | $33.46 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $26.75 | 2024 | Abilify Asimtufii, Abilify Maintena |
| Linus Health, INC. | $25.12 | 2024 | Core Cognitive Evaluation |
| Radius Health, INC. | $21.71 | 2020 | |
| Boston Scientific Corporation | $21.63 | 2022 | |
| Eisai INC. | $18.83 | 2021 | |
| Esperion Therapeutics, INC. | $16.02 | 2025 | Nexletol |
| Daiichi Sankyo INC. | $14.54 | 2025 | Injectafer |
| Echosens North America, INC. | $13.24 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.